IL198592A - Polypeptides binding 4ig-b7h3, nucleic acids encoding same and methods for production and use thereof - Google Patents

Polypeptides binding 4ig-b7h3, nucleic acids encoding same and methods for production and use thereof

Info

Publication number
IL198592A
IL198592A IL198592A IL19859209A IL198592A IL 198592 A IL198592 A IL 198592A IL 198592 A IL198592 A IL 198592A IL 19859209 A IL19859209 A IL 19859209A IL 198592 A IL198592 A IL 198592A
Authority
IL
Israel
Prior art keywords
creating
methods
nucleic acids
acids encode
proteins linked
Prior art date
Application number
IL198592A
Other languages
English (en)
Hebrew (he)
Other versions
IL198592A0 (en
Original Assignee
Macrogenics West Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics West Inc filed Critical Macrogenics West Inc
Publication of IL198592A0 publication Critical patent/IL198592A0/en
Publication of IL198592A publication Critical patent/IL198592A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL198592A 2006-11-08 2009-05-06 Polypeptides binding 4ig-b7h3, nucleic acids encoding same and methods for production and use thereof IL198592A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85811306P 2006-11-08 2006-11-08
US99388207P 2007-09-14 2007-09-14
PCT/US2007/023620 WO2008066691A2 (en) 2006-11-08 2007-11-08 Tes7 and antibodies that bind thereto

Publications (2)

Publication Number Publication Date
IL198592A0 IL198592A0 (en) 2011-08-01
IL198592A true IL198592A (en) 2015-11-30

Family

ID=39468449

Family Applications (1)

Application Number Title Priority Date Filing Date
IL198592A IL198592A (en) 2006-11-08 2009-05-06 Polypeptides binding 4ig-b7h3, nucleic acids encoding same and methods for production and use thereof

Country Status (7)

Country Link
US (2) US7718774B2 (enExample)
EP (1) EP2094307A4 (enExample)
JP (1) JP5601836B2 (enExample)
AU (1) AU2007325872B2 (enExample)
CA (1) CA2668800A1 (enExample)
IL (1) IL198592A (enExample)
WO (1) WO2008066691A2 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2669260C (en) * 2006-11-09 2019-01-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Differential gene expression in physiological and pathological angiogenesis
WO2008100934A1 (en) * 2007-02-14 2008-08-21 Mayo Foundation For Medical Education And Research B7-h3 in cancer
JP5785490B2 (ja) 2008-04-02 2015-09-30 マクロジェニクス，インコーポレーテッド Ｂｃｒ複合体特異的抗体およびその使用方法
CA2733218A1 (en) 2008-07-25 2010-01-28 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
DK2350128T3 (da) 2008-10-22 2014-12-01 Inst Research In Biomedicine Fremgangsmåder til fremstilling af antistoffer fra plasmaceller
ES2733067T3 (es) 2008-12-19 2019-11-27 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
EP2399130A4 (en) * 2009-02-20 2012-06-06 Wayne John Cancer Inst ASSAY OF B7-H3 ANTIBODY-COUPLED BEADS FOR THE ISOLATION AND DETECTION OF CIRCULATING TUMOR CELLS IN THE BODILY FLUIDS OF MELANOMA AND BREAST CANCER PATIENTS
TWI404931B (zh) * 2009-02-20 2013-08-11 財團法人國家同步輻射研究中心 癌化生物樣本之檢測方法及其使用之檢驗試劑
PH12018501083A1 (en) 2010-03-04 2019-02-18 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
WO2012004410A1 (en) * 2010-07-09 2012-01-12 Oslo Universitetssykehus Hf B7-h3 antagonists and taxanes
MX339622B (es) 2010-08-02 2016-06-02 Macrogenics Inc Diacuerpos covalentes y sus usos.
KR102125672B1 (ko) 2011-04-25 2020-06-23 다이이찌 산쿄 가부시키가이샤 항 ｂ７-ｈ３항체
KR102030987B1 (ko) 2011-04-25 2019-11-11 다이이찌 산쿄 가부시키가이샤 항 ｂ７-ｈ３항체
EA201391753A1 (ru) 2011-05-21 2014-08-29 Макродженикс, Инк. Домены, связывающиеся с деиммунизованной сывороткой, и их применение для увеличения времени полужизни в сыворотке
EP3418300B1 (en) 2011-07-18 2020-10-28 Institute for Research in Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
CA2881966C (en) 2012-08-24 2020-10-06 The Regents Of The University Of California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
PT3052192T (pt) 2013-10-02 2020-09-24 Medimmune Llc Anticorpos neutralizantes anti-influenza a e suas utilizações
KR20160135190A (ko) 2014-02-14 2016-11-25 앤드류 에스. 카이 혈관형성 암의 치료를 위한 개선된 방법
CA2954780A1 (en) 2014-07-15 2016-01-21 Medimmune, Llc Neutralizing anti-influenza b antibodies and uses thereof
EP3960761A1 (en) 2015-06-01 2022-03-02 MedImmune, LLC Neutralizing anti-influenza binding molecules and uses thereof
CN108136010A (zh) 2015-10-08 2018-06-08 宏观基因有限公司 用于治疗癌症的联合疗法
IL304940A (en) 2016-01-13 2023-10-01 Medimmune Llc A method for treating type A influenza
CA3020864A1 (en) 2016-04-15 2017-10-19 Macrogenics, Inc. Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
TWI762487B (zh) * 2016-06-08 2022-05-01 美商艾伯維有限公司 抗-b7-h3抗體及抗體藥物結合物
EP3474854A4 (en) 2016-06-27 2020-02-19 The Regents of The University of California CANCER TREATMENT COMBINATIONS
UA125593C2 (uk) 2017-03-31 2022-04-27 Джянгсу Хенгруй Медісін Ко., Лтд. Антитіло в7-н3, його антигензв'язуючий фрагмент та його медичне застосування
MY209065A (en) 2018-09-30 2025-06-18 Jiangsu Hansoh Pharmaceutical Group Co Ltd Anti-b7h3 antibody-exatecan analog conjugate and medicinal use thereof
BR112022000216A2 (pt) 2019-07-11 2022-05-17 Memorial Sloan Kettering Cancer Center Anticorpos direcionados a dll3 e usos dos mesmos
US12590298B2 (en) 2019-10-18 2026-03-31 The Regents Of The University Of California Ex vivo tumor angiogenesis model
EP4045485A1 (en) 2019-10-18 2022-08-24 The Regents Of The University Of California 3-phenylsulphonyl-quinoline derivatives as agents for treating pathogenic blood vessels disorders
WO2021076903A1 (en) * 2019-10-18 2021-04-22 The Regents Of The University Of California Compositions and methods for detecting plxdc1 and plxdc2 in human tissues
CA3155759A1 (en) * 2019-12-13 2021-06-17 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anti-tslp antibody and uses thereof
CN119504997A (zh) 2021-02-09 2025-02-25 苏州宜联生物医药有限公司 生物活性物偶联物及其制备方法和用途

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862925A (en) 1973-07-05 1975-01-28 American Home Prod Preparation of somatotropin release inhibiting factor and intermediates therefor
US3842067A (en) 1973-07-27 1974-10-15 American Home Prod Synthesis of(des-asn5)-srif and intermediates
JPS5726506B2 (enExample) 1974-03-08 1982-06-04
US4105603A (en) 1977-03-28 1978-08-08 The Salk Institute For Biological Studies Peptides which effect release of hormones
USRE30548E (en) 1979-08-31 1981-03-17 The Salk Institute For Biological Studies Peptides which effect release of hormones
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5552391A (en) 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5532159A (en) 1994-04-01 1996-07-02 The Ohio State University Monoclonal antibody to canine placental oncofetal protein for detecting cancer
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
EP0881299A4 (en) * 1996-02-15 2004-12-15 Chugai Seiyakukabushiki Kaisha MONOCLONAL ANTIBODY THAT RECOGNIZES ANTIGENS ON THE SURFACE OF ENDOTHEL CELLS FROM TUMOR SUPPLYING BLOOD VESSELS.
AU4640600A (en) 1999-05-11 2000-11-21 Eli Lilly And Company Amyloid precursor protein protease and related nucleic acid compounds
PT1210428E (pt) 1999-08-23 2015-07-21 Genetics Inst Llc Pd-1, um recetor para b7-4 e suas utilizações
US6429303B1 (en) 1999-09-03 2002-08-06 Curagen Corporation Nucleic acids encoding members of the human B lymphocyte activation antigen B7 family and methods of using the same
US6406840B1 (en) 1999-12-17 2002-06-18 Biomosaic Systems, Inc. Cell arrays and the uses thereof
US20060154313A1 (en) 2000-04-13 2006-07-13 Immunex Corporation Human B7 polypeptide B7-H3A
AU2001264747A1 (en) 2000-05-22 2001-12-03 Idec Pharmaceuticals Corporation Identification of unique binding interactions between certain antibodies and thehuman b7.1 and b7.2 co-stimulatory antigens
WO2001094413A2 (en) 2000-06-06 2001-12-13 Bristol-Myers Squibb Company B7-related nucleic acids and polypeptides and their uses for immunomodulation
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
AU2001283507A1 (en) 2000-07-27 2002-02-13 Mayo Foundation For Medical Education And Research B7-h3 and b7-h4, novel immunoregulatory molecules
EP1327638A4 (en) 2000-09-12 2004-09-29 Kirin Brewery NEW WALL MEMBRANE OF DENDRITIC CELLS AND THEIR USE
US20030134283A1 (en) 2000-10-03 2003-07-17 Peterson David P. Genes regulated in dendritic cell differentiation
AU2001286171B2 (en) 2001-05-25 2008-01-10 Serono Genetics Institute S.A. Human CDNAs and proteins and uses thereof
JP4181032B2 (ja) 2001-05-25 2008-11-12 アムジェン インコーポレーテッド Ｂ７関連タンパク質−２分子およびその使用
US20070015144A9 (en) 2001-05-25 2007-01-18 Genset, S.A. Human cDNAs and proteins and uses thereof
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
AU2002347761A1 (en) 2001-08-02 2003-02-24 Eli Lilly And Company Novel polypeptide analogs and fusions and their methods of use
US20040162236A1 (en) 2002-04-01 2004-08-19 John Alsobrook Therapeutic polypeptides, nucleic acids encoding same, and methods of use
ATE488530T1 (de) 2002-06-19 2010-12-15 Raven Biotechnologies Inc Internalisierende antikörper spezifisch für das raag10 zelloberflächenziel
EP2365004B1 (en) 2002-06-21 2016-01-06 Johns Hopkins University School of Medicine Membrane associated tumor endothelium markers
AU2003248933A1 (en) 2002-07-11 2004-02-02 Incyte Corporation Secreted proteins
AU2003289716A1 (en) 2002-09-12 2004-04-30 Incyte Corporation Molecules for diagnostics and therapeutics
EP2853593B1 (en) 2003-03-07 2017-10-04 DSM IP Assets B.V. Hydrolases, nucleic acids encoding them and mehods for making and using them
US20050002935A1 (en) 2003-04-17 2005-01-06 Vincent Ling Use of B7-H3 as an immunoregulatory agent
CA2463487A1 (en) 2003-04-28 2004-10-28 Auckland Uniservices Limited Tumours treating combinations, compositions and methods
CA2463464A1 (en) 2003-04-28 2004-10-28 Auckland Uniservices Limited Methods of treatment and compositions therefor
WO2005017163A2 (en) 2003-08-15 2005-02-24 Imperial College Innovations Limited Phenotypic knockout of cell-surface proteins
ES2534288T3 (es) * 2004-08-03 2015-04-21 Innate Pharma Composiciones terapéuticas contra el cáncer que seleccionan como objetivo 4Ig-B7-H3
WO2006096834A2 (en) 2005-03-08 2006-09-14 Diversa Corporation Hydrolases, nucleic acids encoding them and methods for improving paper strength
KR101510065B1 (ko) 2005-06-08 2015-04-07 다나-파버 캔서 인스티튜트 인크. 예정 세포사 1(ｐｄ-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물
JP2009518427A (ja) 2005-12-08 2009-05-07 ユニバーシティー オブ ルーイビル リサーチ ファンデーション，インコーポレーテッド Ｉｎｖｉｖｏ細胞表面操作
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白

Also Published As

Publication number Publication date
IL198592A0 (en) 2011-08-01
US20080226634A1 (en) 2008-09-18
US7718774B2 (en) 2010-05-18
CA2668800A1 (en) 2008-06-05
EP2094307A4 (en) 2015-08-26
US8216570B2 (en) 2012-07-10
US20100183605A1 (en) 2010-07-22
AU2007325872A1 (en) 2008-06-05
WO2008066691A2 (en) 2008-06-05
WO2008066691A3 (en) 2008-07-17
JP5601836B2 (ja) 2014-10-08
JP2010508847A (ja) 2010-03-25
AU2007325872B2 (en) 2012-12-13
EP2094307A2 (en) 2009-09-02

Similar Documents

Publication Publication Date Title
IL287292A (en) Cycteine engineering anti-cd79b antibodies and antibody-drug conjugates
EP1856291A4 (en) NUCLEIC ACIDS AND PROTEINS, AND METHODS OF MAKING AND USING SAME
DK2064334T3 (da) Aldehydtags, anvendelser deraf i site-specifik proteinmodificering
BRPI0918947A2 (pt) proteína de fusão de anticorpo
EP1737982A4 (en) NUCLEIC ACID PROGRAMMABLE PROTEIN NETWORKS
DK2617821T3 (da) Phytaser, nukleinsyrer, der koder for disse, og fremgangsmåder til frembringelse og anvendelse heraf
DK1999154T3 (da) Fremstillede heterodimere proteindomæner
WO2008143679A9 (en) Nucleic acids and proteins and methods for making and using them
ES2752025T8 (es) Métodos de cribado de proteínas
DK2046826T3 (da) Exendin-fusionsproteiner
CU23869B1 (es) Anticuerpos anti-esclerostina y proteínas funcionales
BRPI0810482A2 (pt) Métodos de produção de proteína usando compostos antissenescência
DK1877090T3 (da) Trimert ox40-immunoglobulin-fusionsprotein og fremgangsmåder til anvendelse heraf
DK2185574T3 (da) Antistoffer og relaterede molekyler, der bindes til 24P4C12-proteiner
BRPI0920749A2 (pt) proteínas de ligação de antagonista multialvo cd86
DK3136030T3 (da) Fremgangsmåde til lyofilisering
DK2061897T3 (da) Fed-batch-fermenteringsproces med høj celledensitet til fremstilling af rekombinant protein
NO20071302L (no) Bindingdomene fusjonsproteiner
DK1973429T3 (da) Proteinhydrolysater og fremgangsmåde til fremstilling
DK3339445T3 (da) Interleukin -13 bindende proteiner
EP2161287A4 (en) OPTIMIZED TACI FC FUSION PROTEINS
BRPI0820342A2 (pt) Modulação de tráfego de proteína
EP2158210A4 (en) RAGE FUSION PROTEINS
BRPI1016204A2 (pt) proteínas de fusão de anticorpos com sítios de ligação fcrn modificados
EP2172198A4 (en) P27 PROTEIN INDUKTOR

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed